SCHEMBL21836690

SCHEMBL21836690

CCn1nc2c(c1C(=O)c1ccc(OC)cc1)CCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
HPGD P15428 4/20 0.49
GAA P10253 1/20 0.49
TP53 P04637 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 3/20 0.42
TSHR P16473 1/20 0.42
LMNA P02545 6/20 0.41
ALDH1A1 P00352 4/20 0.41
HTT P42858 2/20 0.41
ALOX15 P16050 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
KMT2A Q03164 2/20 0.40
CYP19A1 P11511 1/20 0.40
THRB P10828 1/20 0.40
POLB P06746 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21836694 0.86 MAPT (0.42) KDM4EHPGDGAATP53SMN1; SMN2
SCHEMBL21836666 0.83 UGCG (0.44) KDM4EHPGDGAAMAPTLMNA
SCHEMBL22344794 0.75 POLB (0.40) HPGDMAPTTSHRLMNAALDH1A1
SCHEMBL29445731 0.74 PTGER4 (0.54) KDM4EHPGDGAASMN1; SMN2MAPT
SCHEMBL21836697 0.74 MAPT (0.46) KDM4EHPGDGAATP53MAPT
SCHEMBL21836678 0.72 POLB (0.50) KDM4EHPGDGAAMAPTTSHR
SCHEMBL26690229 0.72 MAPT (0.43) KDM4EHPGDGAATP53SMN1; SMN2
SCHEMBL21191871 0.71 ALDH1A1 (0.43) KDM4EHPGDGAASMN1; SMN2MAPT
SCHEMBL21192221 0.71 TP53 (0.46) KDM4EHPGDTP53SMN1; SMN2MAPT
SCHEMBL26690358 0.70 POLB (0.60) KDM4EHPGDGAAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
CN-108484600-B URAT1 inhibitors for promoting uric acid excretion 江苏新元素医药科技有限公司 2022-12-13 CN disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-08-20 US disclosed
EP-3632904-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2020-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 KDM4E 4052/4885HPGD 2825/4885GAA 341/4885
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION SLC10A6, SLC10A1, SLC28A1 KDM4E 4052/4885HPGD 2825/4885GAA 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.